-
Watson's Generic Lybrel Receives FDA Approval
Tuesday, June 7, 2011 - 8:02am | 96Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories has received approval from the United States Food and Drug Administration for Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09 mg/0.02 mg, the generic equivalent to Pfizer's Lybrel tablets....
-
Citi Discusses Warner Chilcott After Meeting With Company CFO
Tuesday, June 7, 2011 - 7:43am | 112Citi Investment Research has a Buy rating and a $29 price target on shares of Warner Chilcott Plc (NASDAQ: WCRX). In a note to clients, Citi writes, "We Hosted a Dinner with CFO, Paul Herendeen. We recommend buying WCRX's shares, which trade at a trough multiple of 5.4x our ‘12 EPS of $4.14,...
-
Piper Jaffray Raises PT On Corcept Therapeutics To $7
Tuesday, June 7, 2011 - 7:41am | 27Piper Jaffray has raised the price target on Corcept Therapeutics (NASDAQ: CORT) from $6 to $7 and maintains its Overweight rating.
-
Roche and Merck Collaborate to Develop Diagnostic Tests for Merck's Investigational Cancer Therapies
Tuesday, June 7, 2011 - 7:38am | 52Merck (NYSE: MRK) and Roche (RHHBY) today announced that they have entered into a collaboration focused on the application and development of diagnostic assays for use with Merck's investigational cancer therapy portfolio. Financial details were not disclosed.
-
Bank of America Merrill Lynch Maintains Buy on Allergan
Tuesday, June 7, 2011 - 7:33am | 123Bank of America Merrill Lynch is out with its report today on Allergan (NYSE: AGN), maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "We believe that AGN is ideally positioned, with a fully integrated, global, specialty-focused model and strong management team. While...
-
*isoray Acquires Exclusive Worldwide License For Liquid Iodine
Tuesday, June 7, 2011 - 7:31am | 184IsoRay, Inc. (NYSE: ISR) announced today that it has completed a license agreement with Dr. Reddy's Laboratories (NYSE: RDY) for exclusive worldwide licensing rights to Iotrex^®, a liquid iodine radiation, for use in brain cancer treatment. Iotrex^® is a critical component in the GliaSite^®...
-
Simcere Reaches Agreement with Former Shareholders of Jiangsu Quanyi
Tuesday, June 7, 2011 - 6:53am | 158Simcere Pharmaceutical Group (NYSE: SCR) today announced that a settlement agreement with certain former shareholders and directors of Jiangsu Quanyi Biological Technology Stock Co., Ltd. (previously known as Jiangsu Yanshen Biological Technology Stock Co., Ltd) has become effective. The settlement...
-
J.P. Morgan Provides Color on Bristol Myers Squibb and Pfizer
Tuesday, June 7, 2011 - 6:39am | 308J.P. Morgan provided color on Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE). In a research report published today, J.P. Morgan commented on the companies' new drugs. J.P. Morgan is more impressed by Pfizer at the moment. In the report, J.P. Morgan states on BMY's Yervoy, "meaningful...
-
It's Inverted Hammertime! 06-06-2011
Monday, June 6, 2011 - 3:25pm | 947Cusick's Corner With Finance and Energy challenged, plus AAPL under some pressure, the shorts have the strength on their side in spite of Friday's Bullish technical set up that created an inverted hammer. The market looks poised for continued safe haven buying, Gold/Silver, along with continued...
-
Will Prozac Murder Trial Doom Eli Lilly Stock?
Monday, June 6, 2011 - 2:33pm | 394When Judge Robert Heinrichs renders sentence on August 4, will your portfolio be the one to take the fall? On that date, it is expected that the judge will make his rulings on sentencing for a teenage boy, arrested after allegedly killing a fellow teenager in what one doctor calls a clear case of...
-
Amarin Corp. Diving
Monday, June 6, 2011 - 1:51pm | 111Shares of Amarin Corp. (NASDAQ: AMRN) just saw some very heavy selling that caused the stock to fall around 2% in a matter of minutes. The shares are now bouncing back as it looked like some weak hands may have capitulated during the quick move lower. Currently, AMRN is trading down 4.75% to $17.64...
-
Lannett Announces Revised FDA PDUFA Date for Morphine Sulfate Oral Solution NDA
Monday, June 6, 2011 - 1:15pm | 80Lannett Company, Inc. (NYSE: LCI) announced today that the U.S. Food and Drug Administration has issued a revised Prescription Drug User Fee Act goal date of June 23, 2011 for the company's 505(b)(2) New Drug Application for Morphine Sulfate Oral Solution. “With a revised PDUFA date in 17 days,...
-
NASDAQ Stocks Hitting 52-Week Highs
Monday, June 6, 2011 - 10:27am | 145Internet Initiative Japan Inc (NASDAQ: IIJI) shares gained 5.78% to create a new 52-week high of $9.34. IIJI's trailing-twelve-month revenue is $1.03 billion. Hickory Tech Corporation (NASDAQ: HTCO) shares jumped 5.27% to create a new 52-week high of $10.99. HTCO has a dividend yield of 5.20%....
-
Morning Market Losers
Monday, June 6, 2011 - 9:56am | 119Credicorp Ltd (NYSE: BAP) shares moved down 14.68% to $86.75 at 9:55 am. Analysts at Raymond James downgraded BAP from “outperform” to “underperform.” YM BioSciences Inc (AMEX: YMI) dipped 11.44% to $3.25. YM BioSciences announced positive interim safety and efficacy results from the Phase I/II...
-
Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product in Breast Cancer Patients
Monday, June 6, 2011 - 9:21am | 102Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim compared to pegfilgrastim. Lipegfilgrastim, a...